Masimo Corp is primarily active in the medical device industry.

The main competitors of Masimo Corp in the market include companies such as Philips Healthcare, Nihon Kohden Corporation, and Smiths Medical.

Masimo Corp is a leading global medical technology company specializing in noninvasive patient monitoring. Founded in 1989 by Joe Kiani, the company has a rich history of innovation and advancements in the healthcare industry. Masimo Corp's core business revolves around developing and manufacturing advanced monitoring technologies, including pulse oximeters and signal extraction technology. With its commitment to improving patient outcomes and reducing healthcare costs, Masimo Corp has revolutionized the way healthcare professionals monitor patients' vital signs. Today, it is recognized as a trusted name in the medical device industry, providing innovative solutions that enhance patient care and safety worldwide.

Masimo Corp has achieved several significant milestones. Some noteworthy accomplishments include the development of breakthrough technologies in noninvasive patient monitoring, such as SET® pulse oximetry. The company has also received numerous awards and recognition for its innovative products and contributions to the healthcare industry. Masimo Corp has successfully expanded its global presence and formed strategic partnerships with leading healthcare organizations worldwide. Additionally, the company has consistently shown strong financial performance and steady revenue growth over the years. Overall, Masimo Corp continues to make strides in advancing patient care through its cutting-edge technologies and industry leadership.

Masimo Corp is primarily present in various countries and regions across the globe. Some notable markets where the company operates include the United States, European countries like Germany, France, and the United Kingdom, as well as Asian countries including Japan and China. Masimo Corp's global presence enables it to provide its innovative healthcare solutions, including noninvasive patient monitoring technologies, to healthcare facilities and professionals worldwide.

Masimo Corp represents a strong commitment to improving patient outcomes and reducing healthcare costs through innovative medical technologies. The company values include a dedication to patient safety, quality, and continuous improvement. Masimo's corporate philosophy revolves around providing noninvasive monitoring solutions that enable clinicians to make more informed decisions, enhance patient care, and optimize workflows. By combining advanced sensor and signal processing technologies, Masimo Corp strives to address the evolving needs of the medical community. The company's focus on research and development, as well as collaboration with healthcare professionals, reinforces its commitment to pioneering advancements in medical monitoring to benefit patients worldwide.

Analysts currently set an average price target of 180.21 USD for the Masimo stock (median: 183.60 USD), implying +0.1 % versus the latest price. The consensus is based on 16 analyst ratings.

Masimo Analyst Price Targets 2026

15 analysts currently rate the Masimo stock: 7 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Masimo to generate revenue of 1.63 B USD and earnings per share of 5.97 USD.

Masimo Analyst Price Targets 2026

Converted at the current exchange rate, the Masimo share trades at 154.04 EUR (179.95 USD).

The Masimo share (MASI) is listed on 8 stock exchanges, including: NYSE (MASI), NASDAQ (MASI), Frankfurt (3M4.F), München (3M4.MU), Düsseldorf (3M4.DU), London (0JZ2.L), London (0JZ2.L), SIX (Zürich) (3M4.SW).

Masimo Corporation is a leading provider of medical diagnostic and monitoring technologies that aim to make patient care safer and more effective. The company is headquartered in California and operates offices worldwide. Masimo's business model can be roughly divided into three areas: 1. Products and technologies Masimo offers a wide range of medical devices and technologies, including pulse oximeters for monitoring oxygen saturation in the blood, capnographs for monitoring end-tidal carbon dioxide concentration, as well as patient monitors and control systems. A highlight is Masimo's Signal Extraction Technology (SET), which is used in almost all of the company's products. SET uses a special algorithm to filter signals from skin color, movement, and other external sources of interference, allowing for accurate measurements. Additionally, Masimo has developed other innovative technologies, such as automatic measurement of hemoglobin levels, which can lead to improved patient outcomes. 2. Services Masimo also offers various services, such as installation, training, and technical support for its products. Furthermore, the company has entered into partnerships with other companies such as Apple and Philips to jointly develop innovative solutions for patient monitoring. 3. Research and development Masimo invests heavily in the research and development of new products and technologies. The company has filed numerous patents and successfully implemented them. By collaborating with clinics and universities, Masimo ensures that its products have informative features and high quality that meet the needs of patients and medical professionals. Overall, Masimo's business model is designed to make healthcare safer and more effective by developing innovative products and technologies, and by providing services and support to its customers. The wide range of products and technologies, as well as the investments in research and development, indicate that Masimo will continue to play an important role in the medical industry in the future.

The expected revenue of Masimo is 1.63 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Masimo is 323.74 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Masimo is currently 30.13. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Masimo stock.

The price-to-sales ratio (P/S) of Masimo is currently 5.97. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Masimo stock.

The Eulerpool Quality Score for Masimo is 4/10.

The ISIN of Masimo is US5747951003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Masimo is 578074. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Masimo is MASI. The ticker symbol is used to trade Masimo shares on the stock exchange.

The current dividend yield of Masimo is 0.56 %.

Masimo paid dividends every year for the past 0 years.

Masimo is assigned to the 'Health' sector.

To receive the latest dividend of Masimo from amounting to 1 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Masimo are distributed in USD.